Time to give NGTs a chance

Posted on by
Reply

Marco Pasti grows corn, soybeans, wheat, barley, sugar beets, potatoes, some wine grapes and walnuts on his farm near Venice, in Italy. In addition to being a farmer, he is an advocate for science-based agriculture. Don’t miss his opinion piece written for the Global Farmer Network after the European Parliament vote on the New Genomic Techniques last February. After the EU elections next June, the path of the new regulatory framework will resume, which could mark a turning point “in favor of sound science – and possibly a major break from the mistakes of the past when Europeans treated crop innovation with skepticism and even fear.”

A must-read recommended by Doudna, Gates and…

Posted on by
Reply

The Italian publisher did me the crazy honor of including a quote from me on the back cover of the best book of the year (IMHO), along with quotes from CRISPR inventor Jennifer Doudna and Bill Gates. The autobiography of Katalin Karikó, the mRNA vaccine scientist, is a must-read for those who love great science and great minds. We had already blogged about her in the aftermath of the Nobel Prize.

Resurrecting extinct species _ where do we stand?

Posted on by
Reply
Beth Shapiro is chief scientific officer at Colossal Biosciences

Plans to genetically bring mammoths and other vanished animals back to life have scientific stakes far beyond the imagery of Jurassic Park

Continue reading →

Xenotransplant patient is well (fingers crossed)

Posted on by
Reply
Richard Slayman – Credit New York Times

This is good news, to be celebrated with caution. The first patient with a CRISPR-edited pig kidney has left the hospital. A little over two weeks have passed since the surgery at Massachusetts General Hospital, but according to U.S. press reports, Richard Slayman is well enough to have been discharged. Fingers crossed, then, for this 62-year-old man who, thanks to a xeno-rene, no longer needs dialysis.

Continue reading →

CRISPR trials: the 2024 update

Posted on by
Reply

The recent approval of Casgevy represents the first official success of gene editing-based therapies. The treatment for sickle cell anemia and thalassemia came in record time, only 11 years after CRISPR was invented. “Two diseases down, 5,000 to go,” commented Fyodor Urnov, Director of Technology & Translation at the Innovative Genomics Institute. Among the many diseases awaiting a cure, what will be the next to benefit from CRISPR? At what rate can we expect new treatments to arrive? The periodic update published by IGI is a must-read to navigate through hope and hype, papers and press-releases. The picture is overwhelmingly positive, but there is also some cause for disappointment. Here is an excerpt from the introduction:

Continue reading →

CRISPR plants for all tastes

Posted on by
Reply

It could take a while to bring the first CRISPR products to our tables, but it is always a good time to see what progress is being made in the labs. Here are some novelties, reported by Isaaa: high-fiber barley, aromatic soy milk, extralong-grain wheat, TiGER strawberries, and my favorites: seedless, thornless, and higher-yielding blackberries and black raspberries.

Live Dance Performance – The Choreography of CRISPR

Posted on by
Reply

If you are in Cambridge, Massachusetts, don’t miss the live dance performance to be held at the MIT Museum on March 16th. The Choreography of CRISPR is all about “twisting, cutting, inserting, copying, repeating, palindromes, and cluster”, “an intricate dance of spiraling and folding patterns” (you can watch a minute from the première on the facebook page of the NYC-based contemporary dance company Pigeonwing Dance; choreography by Gabrielle Lamb, original music by James Budinich).

CRISPR’s next target is the fetus genome

Posted on by
Reply

The goal is to treat unborn children as early as possible, before their disease causes irreversible damage. But the ambition is to do so without heritable DNA changes, that is, by targeting only somatic tissues and avoiding sex cells. Fetal genome editing, then, differs from embryo editing, which has raised so much controversy in recent years. The best way to understand how far it has come and how much remains to be done is to tell the story of the scientist most committed to this challenge. The opportunity is provided by a longread published in STAT, where Tippi MacKenzie’s biography is interwoven with a review of the field.

Continue reading →

CRISPR plants – what the EU Parliament got right and wrong

Posted on by
Reply

There is no doubt that this is good news: on February 7, the European Parliament approved the Commission’s regulatory proposal on New Genomic Techniques, covering also CRISPR plants. Some of the approved amendments (particularly the one on genetic modification of polyploid plants) have the effect of improving the text, others risk being a problem and should be reconsidered during the trilogue with member states (particularly the requirement to label all final products, even if they do not contain foreign genes). The European Parliament also brought in the issue of non-patentability of NGT plants, which would deserve to be addressed elsewhere. For more information, this is the position expressed on February 14 by European Plant Science Organisation (EPSO).